By Tony Fong

NEW YORK (GenomeWeb News) – Despite an uncertain economy and softness in key end markets, genomic tools and molecular diagnostics firms continued to invest in new technologies as R&D spending through the first half of 2011 rose 13 percent year over year among the firms tracked in the GenomeWeb Daily News Index.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.